Preliminary result of mixed bacterial vaccine as adjuvant treatment of hepatocellular carcinoma.
Mixed bacterial vaccine (MBV) was employed in the multi-modality treatment of hepatocellular carcinoma (HCC) during 1985-1988. Thirty eight patients undergoing palliative resection and cisplatin therapy (Series 1) and 48 patients with unresectable HCC who received hepatic artery ligation + intraarterial cisplatin infusion + radiotherapy (Series 2) were randomized to receive MBV or not. In series 1, the 1- and 2-year survival rates of MBV group and control were 75% vs 58% (P = 0.19) and 45% vs 39% (P = 0.23). In series 2, the 1-, 2- and 3-year survival rates were 59%, 41% and 41% for MBV group and 39%, 25% and 20% for the control, respectively (P1 = 0.07, P2 = 0.09, P3 = 0.07). In addition, MBV improved the "second look" resection rate to 40% as compared to 17% in the control (P greater than 0.05). MBV could also prevent such immunosuppression as decrease of macrophage activity caused by radiotherapy. We consider MBV a potential nonspecific immunostimulant in the multimodality treatment of HCC.
Tang
Z Y
ZY
Liver Cancer Institute, Zhong Shan Hospital, Shanghai Medical University, Peoples Republic of China.
Zhou
H Y
HY
Zhao
G
G
Chai
L M
LM
Zhou
M
M
Lu
J Z
JZ
Liu
K D
KD
Havas
H F
HF
Nauts
H C
HC
D000328:Adult; D000368:Aged; D001428:Bacterial Vaccines / Q000009:adverse effects / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000628:therapy*; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000628:therapy*; D008264:Macrophages / Q000502:physiology; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000502:physiology; D012086:Reoperation; D015996:Survival Rate
D001428:Bacterial Vaccines; D002945:Cisplatin